|
04 May 2022 |
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
|
|
02 May 2022 |
Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
|
02 May 2022 |
Ingenia Therapeutics & Mosaic Biosciences Present Preclinical Data on the Variants of the Bispecific Antibody IGT-427 for the Treatment of Degenerative Retinal Diseases
|
|
02 May 2022 |
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
|
|
02 May 2022 |
Junshi Biosciences and Coherus Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
|
|
02 May 2022 |
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi
|
|
01 May 2022 |
Inmagene Receives FDA's IND Clearance for OX40 Antagonist
|
|
01 May 2022 |
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
|
|
01 May 2022 |
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer
|
|
01 May 2022 |
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
|
|
28 Apr 2022 |
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
|
|
28 Apr 2022 |
Ultomiris approved in the US for adults with generalised myasthenia gravis
|
|
28 Apr 2022 |
Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study
|
|
26 Apr 2022 |
SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer
|
|
26 Apr 2022 |
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
|
|
21 Apr 2022 |
Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1
|
|
21 Apr 2022 |
Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations
|
|
20 Apr 2022 |
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
|
|
20 Apr 2022 |
Sanyou Bio congratulates Dragon Boat Pharmaceutical on the approval of clinical trials of anti-CLDN18.2 antibody drug BC008
|
|
20 Apr 2022 |
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
|
|
19 Apr 2022 |
Enhertu granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
|
|
19 Apr 2022 |
Amgen announces positive top-line results from phase 3 study of ABP 654, biosimilar candidate to Stelara (ustekinumab)
|
|
15 Apr 2022 |
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
|
|
15 Apr 2022 |
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
|
|
14 Apr 2022 |
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
|
